Myogen

Feb 21, 06
	NEW STORY
08:01 ET	Darusentan Phase 2b Data to be Presented at ACC.06
Feb 13, 06
08:31 ET	Myogen Reports Positive Top Line Results for Ambrisentan LFT Rescue Study In Pulmonary Arterial Hypertension
Feb 06, 06
08:05 ET	Myogen to Announce 2005 Results on March 6, 2006
Feb 02, 06
16:30 ET	Myogen Announces Sale of Myogen GmbH
08:02 ET	Myogen to Present at the JP Morgan Small Cap Conference
Jan 30, 06
16:02 ET	Myogen to Present at the NASDAQ US Small Cap Conference
Jan 05, 06
16:00 ET	Myogen to Present at the JPMorgan Healthcare Conference
Dec 16, 05
09:00 ET	Dr. Judith A. Hemberger Appointed to Myogen Board of Directors
Dec 12, 05
07:31 ET	Myogen Reports Positive Top Line Results for Ambrisentan Phase 3 Trial in Pulmonary Arterial Hypertension
Nov 16, 05
17:13 ET	Myogen Files Shelf Registration Statement
Nov 10, 05
16:02 ET	Myogen Announces Achievement of Target Enrollment for Pivotal Phase 3 ARIES-1 Trial of Ambrisentan in PAH
Nov 02, 05
16:00 ET	Myogen Reports 2005 Third Quarter Results
Oct 24, 05
07:03 ET	Myogen to Present at the CIBC World Markets Healthcare Conference
Oct 20, 05
07:04 ET	Myogen to Announce 2005 Third Quarter Results on November 2, 2005
Sep 22, 05
16:00 ET	Myogen to Present at the UBS Global Life Sciences Conference
Sep 21, 05
16:30 ET	Myogen Completes $125 Million Public Offering of Common Stock
Sep 16, 05
06:30 ET	Myogen Prices Public Offering of Common Stock
Sep 08, 05
06:30 ET	Myogen Announces Public Offering of Common Stock
Aug 18, 05
07:00 ET	Myogen Reports Positive Results for Darusentan Phase 2b Trial in Resistant Hypertension
Aug 11, 05
16:01 ET	Myogen Announces Publication of Ambrisentan Data in Two Scientific Journals
Aug 01, 05
16:03 ET	Myogen Reports 2005 Second Quarter Results
Jul 21, 05
16:13 ET	Myogen Announces Completion of Enrollment for Pivotal Phase 3 ARIES-2 Trial of Ambrisentan in PAH
Jul 20, 05
16:31 ET	Myogen to Announce 2005 Second Quarter Results on August 1, 2005
Jun 26, 05
20:30 ET	Myogen Reports Results for Phase 3 Enoximone Trials in Chronic Heart Failure
Jun 03, 05
16:15 ET	Myogen Files Shelf Registration Statement
May 26, 05
08:00 ET	Myogen Announces Expansion of Drug Discovery Collaboration
May 23, 05
16:30 ET	Ambrisentan PAH Long-Term Safety and Efficacy Data Presented at ATS 2005 San Diego
May 19, 05
16:00 ET	Myogen Initiates Trial of Ambrisentan in Patients Who Previously Failed Other ERA Therapy
May 02, 05
16:00 ET	Myogen Reports 2005 First Quarter Results
06:31 ET	Ambrisentan Granted Orphan Drug Designation By the Commission of the European Communities
Apr 28, 05
06:32 ET	Myogen to Present at the Needham & Company Biotechnology Conference
Apr 19, 05
18:30 ET	Enrollment Completed in Phase 2b Trial of Darusentan in Patients With Resistant Systolic Hypertension
Apr 18, 05
16:00 ET	Myogen to Announce 2005 First Quarter Results on May 2, 2005
Mar 24, 05
16:00 ET	Myogen to Present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
Mar 09, 05
16:00 ET	Michael J. Valentino Appointed to Myogen Board of Directors
Feb 28, 05
16:00 ET	Myogen Reports 2004 Year-End Results
Feb 25, 05
11:31 ET	Myogen to Present at the Leerink Swann Health Care Conference
Feb 18, 05
16:55 ET	Myogen to Announce 2004 Results on February 28, 2005
Feb 10, 05
17:10 ET	Ambrisentan PAH Long-Term Safety and Efficacy Data to Be Presented at ATS 2005 - San Diego
Feb 02, 05
18:30 ET	Myogen Updates Ambrisentan Clinical Development Guidance
Jan 03, 05
16:05 ET	Myogen to Present at the JP Morgan Healthcare Conference
Dec 13, 04
16:05 ET	Myogen to Present at the Wachovia Securities 10 for '05 Biotechnology Conference
Dec 03, 04
07:00 ET	Myogen to Present at First Albany Capital Annual Growth Conference
Dec 02, 04
16:10 ET	Myogen Appoints Andrew D. Dickinson Vice President, General Counsel and Secretary
Nov 30, 04
06:00 ET	Myogen Announces Completion of Treatment Phase of Pivotal Phase III Trials of Enoximone in Chronic Heart Failure
Nov 22, 04
17:30 ET	Myogen to Present at the Lazard Life Sciences Conference
Nov 15, 04
16:00 ET	Myogen to Present at Credit Suisse First Boston's Healthcare Conference
Nov 03, 04
06:00 ET	Myogen Reports 2004 Third Quarter Results
Oct 28, 04
06:02 ET	Myogen to Present at CIBC World Markets' Fifteenth Annual Healthcare Conference
Oct 26, 04
17:46 ET	Myogen to Announce 2004 Third Quarter Results on November 3, 2004
Sep 28, 04
07:32 ET	Myogen Updates Clinical Development and Financial Guidance
Sep 27, 04
06:01 ET	Myogen Announces $60 Million Private Financing
Sep 08, 04
06:30 ET	Enoximone Data to Be Presented at HFSA Annual Scientific Meeting
Aug 05, 04
06:30 ET	Myogen Reports 2004 Second Quarter Results
Aug 03, 04
06:30 ET	U.S. FDA Grants Orphan Drug Designation for Ambrisentan
Jul 27, 04
16:15 ET	Myogen to Announce 2004 Second Quarter Results on August 5, 2004
Jul 15, 04
06:30 ET	Myogen Initiates Phase II Clinical Trial of Darusentan for Resistant Systolic Hypertension
Jul 14, 04
20:42 ET	Myogen to Host Investor Day
Jun 22, 04
06:00 ET	Myogen to Participate in Punk Ziegel Pah Investor Symposium
Jun 14, 04
07:02 ET	Myogen to Present at Needham & Company Biotechnology Conference
Jun 07, 04
07:31 ET	Myogen to Present at Pacific Growth Equities Life Sciences Conference
May 24, 04
20:50 ET	Ambrisentan Phase II Results Presented at ATS 2004
May 20, 04
07:30 ET	Myogen Announces Completion of Enrollment in Pivotal Phase III Essential Trials
Apr 29, 04
16:31 ET	Myogen Reports 2004 First Quarter Results
Apr 22, 04
16:24 ET	Myogen to Announce 2004 First Quarter Results on April 29, 2004
Apr 21, 04
16:20 ET	Myogen to Present at CIBC World Markets Biotechnology & Specialty Pharmaceuticals Conference
Mar 25, 04
16:20 ET	Myogen Reports Preliminary Results for EMOTE
Feb 18, 04
08:15 ET	Myogen Reports 2003 Fourth Quarter and Full Year Results
Feb 16, 04
16:00 ET	Ambrisentan Phase II PAH Data to be Presented at ATS 2004
Feb 04, 04
16:33 ET	Kirk Calhoun Appointed to Myogen Board of Directors
Jan 29, 04
16:56 ET	Myogen to Announce 2003 Fourth Quarter and Year-End Results on February 18, 2004
Jan 08, 04
08:06 ET	Myogen Initiates Phase III Trials of Ambrisentan
Dec 23, 03
17:08 ET	Myogen to Present at JPMorgan Healthcare Conference
Dec 04, 03
16:19 ET	Myogen Reports Third Quarter 2003 Results
Nov 21, 03
07:00 ET	Myogen to Announce Third Quarter Results on December 4, 2003
Nov 06, 03
16:48 ET	Myogen Announces Exercise of Underwriter's Over-Allotment Option
Oct 30, 03
07:03 ET	Myogen Announces Pricing of Its Initial Public Offering
Oct 13, 03
09:43 ET	Myogen Announces Drug Discovery Collaboration With Novartis Institutes For Biomedical Research
Aug 28, 03
14:26 ET	Myogen Files Registration Statement for Initial Public Offering
Aug 27, 03
16:33 ET	Myogen Raises $40 Million in Private Placement
Jun 26, 03
07:31 ET	Myogen Announces Discovery in the Treatment of Heart Failure and Cardiac Hypertrophy
Nov 07, 02
11:03 ET	Myogen Awarded SBIR Grant From National Institutes of Health
Oct 31, 02
14:17 ET	Myogen Appoints Jerry T. Jackson to its Board of Directors
Jul 16, 02
08:07 ET	Myogen Adds to Its Management Team With the Appointment Of Vice President of Corporate Development
May 08, 02
08:05 ET	Myogen Announces Findings Supporting Its Early Stage Heart Failure Research Programs
Mar 13, 02
08:03 ET	Ambrisentan Inhibits Stent-Induced Restenosis
Feb 20, 02
08:08 ET	Myogen Adds to Its Management Team With the Appointment Of Senior Vice President of Clinical Development and Regulatory Affairs
Feb 06, 02
08:07 ET	Myogen, Inc. Begins Phase III Pivotal Enoximone Trial
Jan 03, 02
08:02 ET	Myogen, Inc. Closes Private Placement at $66.4 Million